Concord Biotech Limited files acquisition intimation with NSE

M&A / JV 20 Jun 2026 · Announced· ✓ Verified

Concord Biotech Limited, a listed pharmaceutical/biotech entity, filed an intimation of acquisition with the National Stock Exchange on 20 June 2026 (ref: NSE corporate action, timestamp 18:37:31). The NSE filing cover page is the only publicly accessible source confirming the acquisition event. The target entity, acquisition value, payment structure, conditions precedent, and timeline for completion are not disclosed in currently available public documents. Absence of a detailed company press release or full NSE schedule limits corroboration.

Why it mattersAcquirer is listed (NSE filing required), but substantive deal terms and regulatory approvals cannot yet be assessed without access to the complete intimation schedule; monitor for follow-up BSE/NSE detailed announcement or regulatory clearance filings.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals